156 related articles for article (PubMed ID: 7542198)
1. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules.
Gnjatic S; Bressac-de Paillerets B; Guillet JG; Choppin J
Eur J Immunol; 1995 Jun; 25(6):1638-42. PubMed ID: 7542198
[TBL] [Abstract][Full Text] [Related]
2. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
3. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
4. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ
Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389
[TBL] [Abstract][Full Text] [Related]
5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
6. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
7. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs.
DiBrino M; Tsuchida T; Turner RV; Parker KC; Coligan JE; Biddison WE
J Immunol; 1993 Dec; 151(11):5930-5. PubMed ID: 7504010
[TBL] [Abstract][Full Text] [Related]
8. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
[TBL] [Abstract][Full Text] [Related]
9. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.
Nijman HW; Houbiers JG; van der Burg SH; Vierboom MP; Kenemans P; Kast WM; Melief CJ
J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):121-6. PubMed ID: 7506574
[TBL] [Abstract][Full Text] [Related]
11. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
Bertholet S; Iggo R; Corradin G
Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells.
Papadopoulos KP; Hesdorffer CS; Suciu-Foca N; Hibshoosh H; Harris PE
Clin Cancer Res; 1999 Aug; 5(8):2089-93. PubMed ID: 10473091
[TBL] [Abstract][Full Text] [Related]
14. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
[TBL] [Abstract][Full Text] [Related]
15. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides.
Sutton J; Rowland-Jones S; Rosenberg W; Nixon D; Gotch F; Gao XM; Murray N; Spoonas A; Driscoll P; Smith M
Eur J Immunol; 1993 Feb; 23(2):447-53. PubMed ID: 7679646
[TBL] [Abstract][Full Text] [Related]
16. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
17. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
18. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
19. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
[TBL] [Abstract][Full Text] [Related]
20. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
